|
| |
Arrien Pharmaceuticals is a small molecule targeted therapeutics drug discovery and development company working towards targeting kinase signaling pathways - A target class in treating neurodegenerative, Cancer, Inflammatory and Metabolic diseases. The Arrien is applying its proprietary platform to successfully discover a portfolio of uniquely identified IND ready stage programs on Parkinson's, Multiple Sclerosis Diseases (PD, MS), Cancer (Ovarian, Breast, Prostate, Lung, DLBCL, NSCLC and GBM), Rheumatoid Arthritis (RA) and Diabesity diseases.
The name "Arrien" means Noble - A Noble cause for treating unmet medical needs.
Arrien Fragment-Field Drug Design (FFDD™) Technology typically involves scaffold-based design strategy, extensively applies structural biology data inputs to assist Medicinal Chemistry in early phase of lead-to-drug-lead creation process along with its target focused scaffold-like libraries to design new lead candidates within various families of protein kinase drug targets. Arrien cost-competent approach assists its technology to influence target-specific Medicinal Chemistry for multiple protein targets. Moreover, Arrien technology has proven in the identification of potent and highly selective protein kinase inhibitors.
Arrien Pharmaceuticals advanced its Candidate Ready ORS-1104 program for IND enabling studies for the Parkinson's, Diseases indication. Our anticipated enabling studies to complete by Q4 2013. Other therapeutics pipeline programs are in advanced pre-clinical stage of development includes; Lead Candidate Ready ARN-4079, ARN-3236, ARN-6021 for Rheumatoid Arthritis (RA), Multiple Cancer Indications and Multiple Sclerosis diseases. Arrien Pharmaceuticals distinctively placed in developing these targeted therapeutics.
Arrien competitive and unique drug discovery approaches coupled with experienced scientific/management team, expertise in Medicinal/Computational Chemistry, Biological and Clinical Sciences has been the key to company's technology since its operations in Q1 2011.
Our success is based on our experiences and expertise to discover and develop molecular targeted therapeutics that enables a change in how patients are treated.
|
